Deletion of FOXL2 by CRISPR promotes cell cycle G0/G1 restriction in KGN cells

Tang,Bin; Zhang,Yujie; Zhang,Wei; Zhu,Yuqing; Yuan,Shaopeng

doi:10.3892/ijmm.2018.3956

Deletion of FOXL2 by CRISPR promotes cell cycle G0/G1 restriction in KGN cells

Authors:
- Bin Tang
- Yujie Zhang
- Wei Zhang
- Yuqing Zhu
- Shaopeng Yuan
View Affiliations

Affiliations: Department of International Medicine, China Japan Friendship Hospital, Beijing 100029, P.R. China, Shandong Provincial Key Laboratory of Plastic and Microscopic Repair Technology, Institute of Plastic Surgery, Weifang Medical University, Weifang, Shandong 461042, P.R. China, Beijing Ruijian Technology Co., Ltd., Beijing 100086, P.R. China
Published online on: October 24, 2018 https://doi.org/10.3892/ijmm.2018.3956
Pages: 567-574

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Forkhead box L2 (FOXL2), a member of the forkhead family of transcription factors, is important in eyelid and ovary differentiation. Although the function of FOXL2 in organogenesis has been investigated, the detailed mechanisms by which FOXL2 mediates cellular process remain to be fully elucidated. Few FOXL2‑knockout cell lines have been reported, which has limited molecular mechanism investigations. CRISPR is a novel gene editing technique that has been widely used in human genetic diseases. In the present study, FOXL2 was disrupted using clustered regularly interspaced short palindromic repeats (CRISPR), and screening of a stable knockout cell line was performed in human ovarian granulosa KGN cells. Three sites (F404, F425 and F446) around the ATG start codon on the FOXL2 DNA sequence were constructed in a guide RNA lentivirus. Targeting F425 was most efficient, and western blot analysis and DNA sequencing of the resulting cells suggested that both FOXL2 alleles were fully disrupted. In addition, flow cytometry results indicated that the knockout of FOXL2 restricted cell cycle progression at the G0/G1 phase. In addition, the expression levels of cell cycle mediators cyclin D1 and cyclin‑dependent kinase 4 were reduced. These results confirmed that FOXL2 disruption in KGN cells is associated with the cell cycle attenuation.

View Figures

View References

1	Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, et al: The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet. 27:159–166. 2001. View Article : Google Scholar : PubMed/NCBI
2	Cocquet J, Pailhoux E, Jaubert F, Servel N, Xia X, Pannetier M, De Baere E, Messiaen L, Cotinot C, Fellous M and Veitia RA: Evolution and expression of FOXL2. J Med Genet. 39:916–921. 2002. View Article : Google Scholar : PubMed/NCBI
3	Loffler KA, Zarkower D and Koopman P: Etiology of ovarian failure in blepharophimosis ptosis epicanthus inversus syndrome: FOXL2 is a conserved, early-acting gene in vertebrate ovarian development. Endocrinology. 144:3237–3243. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ottolenghi C, Omari S, Garcia-Ortiz JE, Uda M, Crisponi L, Forabosco A, Pilia G and Schlessinger D: Foxl2 is required for commitment to ovary differentiation. Hum Mol Genet. 14:2053–2062. 2005. View Article : Google Scholar : PubMed/NCBI
5	Burns KH, Owens GE, Fernandez JM, Nilson JH and Matzuk MM: Characterization of integrin expression in the mouse ovary. Biol Reprod. 67:743–751. 2002. View Article : Google Scholar : PubMed/NCBI
6	Uhlenhaut NH, Jakob S, Anlag K, Eisenberger T, Sekido R, Kress J, Treier AC, Klugmann C, Klasen C, Holter NI, et al: Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell. 139:1130–1142. 2009. View Article : Google Scholar : PubMed/NCBI
7	Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC and Treier M: The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development. 131:933–942. 2004. View Article : Google Scholar : PubMed/NCBI
8	Kalfa N, Philibert P, Patte C, Ecochard A, Duvillard P, Baldet P, Jaubert F, Fellous M and Sultan C: Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. Fertil Steril. 87:896–901. 2007. View Article : Google Scholar : PubMed/NCBI
9	Moumne L, Batista F, Benayoun BA, Nallathambi J, Fellous M, Sundaresan P and Veitia RA: The mutations and potential targets of the forkhead transcription factor FOXL2. Mol Cell Endocrinol. 282:2–11. 2008. View Article : Google Scholar
10	Rosario R, Araki H, Print CG and Shelling AN: The transcriptional targets of mutant FOXL2 in granulosa cell tumours. PLoS One. 7:e462702012. View Article : Google Scholar : PubMed/NCBI
11	Horvath P and Barrangou R: CRISPR/Cas, the immune system of bacteria and archaea. Science. 327:167–170. 2010. View Article : Google Scholar : PubMed/NCBI
12	Terns MP and Terns RM: CRISPR-based adaptive immune systems. Curr Opin Microbiol. 14:321–327. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wiedenheft B, Sternberg SH and Doudna JA: RNA-guided genetic silencing systems in bacteria and archaea. Nature. 482:331–338. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR and Joung JK: Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 31:227–229. 2013. View Article : Google Scholar : PubMed/NCBI
15	Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science. 339:819–823. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F and Jaenisch R: One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 153:910–918. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wang T, Wei JJ, Sabatini DM and Lander ES: Genetic screens in human cells using the CRISPR-Cas9 system. Science. 343:80–84. 2014. View Article : Google Scholar
18	Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG and Zhang F: Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 343:84–87. 2014. View Article : Google Scholar :
19	Lee PC, Truong B, Vega-Crespo A, Gilmore WB, Hermann K, Angarita SA, Tang JK, Chang KM, Wininger AE, Lam AK, et al: Restoring ureagenesis in hepatocytes by CRISPR/Cas9-mediated genomic addition to arginase-deficient induced pluripotent stem cells. Mol Ther Nucleic Acids. 5:e3942016. View Article : Google Scholar : PubMed/NCBI
20	Tu Z, Yang W, Yan S, Guo X and Li XJ: CRISPR/Cas9: A powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. Mol Neurodegener. 10:352015. View Article : Google Scholar : PubMed/NCBI
21	Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong JW and Xi JJ: Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 23:465–472. 2013. View Article : Google Scholar : PubMed/NCBI
22	Yao S, He Z and Chen C: CRISPR/Cas9-mediated genome editing of epigenetic factors for cancer therapy. Hum Gene Ther. 26:463–471. 2015. View Article : Google Scholar : PubMed/NCBI
23	Gebler C, Lohoff T, Paszkowski-Rogacz M, Mircetic J, Chakraborty D, Camgoz A, Hamann MV, Theis M, Thiede C and Buchholz F: Inactivation of cancer mutations utilizing CRISPR/Cas9. J Natl Cancer Inst. 109:pii: djw1832016. View Article : Google Scholar
24	Kawamura N, Nimura K, Nagano H, Yamaguchi S, Nonomura N and Kaneda Y: CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells. Oncotarget. 6:22361–22374. 2015. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
26	Verdin H and De Baere E: FOXL2 impairment in human disease. Horm Res Paediatr. 77:2–11. 2012. View Article : Google Scholar : PubMed/NCBI
27	Tran S, Zhou X, Lafleur C, Calderon MJ, Ellsworth BS, Kimmins S, Boehm U, Treier M, Boerboom D and Bernard DJ: Impaired fertility and FSH synthesis in gonadotrope-specific Foxl2 knockout mice. Mol Endocrinol. 27:407–421. 2013. View Article : Google Scholar : PubMed/NCBI
28	Shi F, Ding S, Zhao S, Han M, Zhuang Y, Xu T and Wu X: A piggyBac insertion disrupts Foxl2 expression that mimics BPES syndrome in mice. Hum Mol Genet. 23:3792–3800. 2014. View Article : Google Scholar : PubMed/NCBI
29	Doudna JA and Charpentier E: Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 346:12580962014. View Article : Google Scholar : PubMed/NCBI
30	Hsu PD, Lander ES and Zhang F: Development and applications of CRISPR-Cas9 for genome engineering. Cell. 157:1262–1278. 2014. View Article : Google Scholar : PubMed/NCBI
31	Harrison MM, Jenkins BV, O’Connor-Giles KM and Wildonger J: A CRISPR view of development. Genes Dev. 28:1859–1872. 2014. View Article : Google Scholar : PubMed/NCBI
32	Sander JD and Joung JK: CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 32:347–355. 2014. View Article : Google Scholar : PubMed/NCBI
33	Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, et al: DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 31:827–832. 2013. View Article : Google Scholar : PubMed/NCBI
34	Asghar U, Witkiewicz AK, Turner NC and Knudsen ES: The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015. View Article : Google Scholar : PubMed/NCBI
35	Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH and Bilezikjian LM: FoxL2 and Smad3 coordinately regulate follistatin gene transcription. J Biol Chem. 284:7631–7645. 2009. View Article : Google Scholar :
36	Huang SM, Lu KT and Wang YC: ATM/ATR and SMAD3 pathways contribute to 3-indole-induced G₁ arrest in cancer cells and xenograft models. Anticancer Res. 31:203–208. 2011.PubMed/NCBI